Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)

Trial ID # NCT02726997
Phase I/II
Drug Class Immunotherapy: Checkpoint Inhibitors/PD-L1
Drug Name Durvalumab
Alternate Drug Names Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi
Drugs in Trial Carboplatin, Durvalumab, Paclitaxel
Eligible Participant

Newly diagnosed stage III/IV ovarian cancer (neo-adjuvant)

Patients Enrolled

18 (50% stage III, 50% stage IV)

Therapy Setting


Study Design

Open-Label, Non-randomized


PFS, evaluated per RECIST


83% obtained optimal cytoreduction at surgery
PFS: 14.5 months

Clinically Significant Adverse Events

Serious AE:
Grade 3-4 AE:


Durvalumab with chemotherapy in upfront ovarian cancer and continued as maintenance is safe and shows reasonable efficacy


Westin SN et al. Pharmacodynamic changes by durvalumab in combination with chemotherapy in women with untreated, advanced stage ovarian cancer. AACR (2020) abstract CT188

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.